INT315800

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 8.09
Pain Relevance 0.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)
Anatomy Link Frequency
B-cell 5
stem cell 1
Tst (Mus musculus)
Pain Link Frequency Relevance Heat
depression 28 99.28 Very High Very High Very High
Serotonin 11 98.24 Very High Very High Very High
antidepressant 14 90.60 High High
monoamine 7 76.24 Quite High
withdrawal 1 64.48 Quite High
imagery 27 58.16 Quite High
vincristine 9 39.48 Quite Low
positron emission tomography 54 5.00 Very Low Very Low Very Low
corticosteroid 27 5.00 Very Low Very Low Very Low
palliative 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 117 100.00 Very High Very High Very High
Leukemia 9 100.00 Very High Very High Very High
Lymphatic System Cancer 612 99.88 Very High Very High Very High
Depressive Disorder 3 99.88 Very High Very High Very High
Depression 34 99.28 Very High Very High Very High
Recurrence 27 98.24 Very High Very High Very High
Acute Myeloid Leukemia 117 97.74 Very High Very High Very High
Myelodysplastic Syndromes 126 97.66 Very High Very High Very High
Sprains And Strains 150 94.96 High High
Stress 13 93.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While no animal model can fully recapitulate the range of symptoms associated with depressive disorders, the relevance of the TST and FST to human depression has been extensively documented.
Localization (relevance) of TST associated with depression and depressive disorder
1) Confidence 0.54 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.78 Pain Relevance 0.36
To address this possibility, we looked for an association between SNP variants and TST immobility for known coding SNPs in Tph2, Slc6a4, all serotonin receptors, and the genes for corticotrophin releasing hormone (Crh) and the Crh receptors.
Localization (immobility) of TST associated with serotonin
2) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 0.59 Pain Relevance 0.35
Due to wide variations in bioclearance of 131I-TST, dosing is individualized for each patient.
Localization (bioclearance) of 131I-TST
3) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.44 Pain Relevance 0
Seventy-eight RTX naïve patients with refractory or relapsed low grade NHL were randomized between TST and 131I-TST.
Localization (randomized) of 131I-TST associated with lymphatic system cancer
4) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.21 Pain Relevance 0
In a multicenter, single-arm trial, 47 patients with relapsed or refractory B-cell NHL were treated with 131I-TST.
Localization (treated) of 131I-TST in B-cell associated with lymphatic system cancer
5) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.24 Pain Relevance 0
Furthermore, residual RTX remains in patients’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.


Localization (localization) of 131I-TST in B-cell associated with lymphatic system cancer and cancer
6) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.94 Pain Relevance 0
Thus, the majority of patients who receive 131I-TST can still receive additional therapy after relapse.34

Dose escalation with autologous stem cell transplant

Localization (receive) of 131I-TST in stem cell associated with recurrence
7) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.57 Pain Relevance 0
Seventy-eight RTX naïve patients with refractory or relapsed low grade NHL were randomized between TST and 131I-TST.
Localization (randomized) of TST associated with lymphatic system cancer
8) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.21 Pain Relevance 0
Furthermore, residual RTX remains in patients’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.


Localization (localization) of 131I-TST in B-cell associated with lymphatic system cancer and cancer
9) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.87 Pain Relevance 0
The annualized incidence of AML/MDS was 1.6%/year which is similar to that of patients treated with multiple chemotherapy regimens.29 In a study of 76 patients treated with upfront 131I-TST monotherapy for follicular NHL, no patients developed MDS/AML with a median follow-up of 7.93 years.30 Distinguishing the attributable risk of MDS/AML to chemotherapy or 131I-TST is difficult, although it appears that 131I-TST does not significantly increase the risk of leukemia.29

131I-TST in relapsed B-cell NHL

Localization (risk) of 131I-TST in B-cell associated with leukemia, lymphatic system cancer, myelodysplastic syndromes and acute myeloid leukemia
10) Confidence 0.48 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 2.10 Pain Relevance 0
This cold (nonradioactive) antibody is thought to saturate both nonspecific binding sites and CD20 binding sites on normal B cells, especially in B cell reservoirs such as the spleen, and thus improve tumor localization of the hot (radioactive) antibody.22 Next, a dosimetric dose of 131I-TST with 5 mCi 131I conjugated to 35 mg TST is infused over 20 minutes.
Localization (localization) of 131I-TST in B cell associated with cancer
11) Confidence 0.45 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.16 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox